

Gradman Josefine (Orcid ID: 0000-0002-3196-6655)

**Title:** Oral food challenge with raw egg: sixty minute compared with thirty minute dosing interval

**Authors:**

Josefine Gradman<sup>1</sup>, Birgitte Tusgaard Petersen<sup>1,2</sup>, Susanne Halken<sup>1</sup>

**Institutional affiliations:**

<sup>1</sup> Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark

<sup>2</sup> Department of Pediatrics, Viborg County Hospital, Viborg, Denmark

Corresponding author:

Josefine Gradman

ORCID: 0000-0002-3196-6655

Josefine.gradman@rsyd.dk

**Key messages**

- We compared outcomes for raw egg food challenges using 30 or 60 minute dosing intervals
- A 60 minutes dosing interval was associated with more first dose reactions
- A 60 minute dosing interval was associated with less symptoms but similar adrenaline use

**Key words**

allergen, dosing interval, egg white, food allergy, oral food challenge

**Acknowledgments**

OPEN, Open Patient data Explorative Network, Odense University Hospital, Region of Southern Denmark

**Conflicts of interest**

The authors declare no conflicts of interest in relation to this work.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the [Version of Record](https://doi.org/10.1111/cea.14187). Please cite this article as doi: [10.1111/cea.14187](https://doi.org/10.1111/cea.14187)

This article is protected by copyright. All rights reserved.

To the Editor,

Allergies to egg and milk are the most common food allergies in European children. The prevalence of IgE-mediated allergy to egg in 2-year-olds is about 1.6% and even higher in children with atopic dermatitis.

An oral food challenge (OFC) is the gold standard to diagnose IgE-mediated food

Allergy. The time from ingestion to an allergic reaction may differ between allergens and the few available clinical studies on dosing intervals support that egg may elicit an allergic reaction later than milk.<sup>(1-3)</sup> During several years of daily clinical practice, we have experienced that children during OFC with raw egg, often react more than 30 minutes after ingesting the final dose.

Consequently, on February 1, 2019, we changed our egg OFC protocol from 30-minutes to 60-minutes dosing intervals. In order to keep the cumulative dose constant without increasing the total OFC time significantly, the number of doses was reduced and the last two doses equivalent increased. The aim was to investigate if a longer time interval between fewer but larger doses would overall cause milder reactions in egg allergic children.

All children aged 0-18 years evaluated for Type 1 allergy to hen's egg at the Pediatric Allergy Unit at Hans Christian Andersen Children's Hospital, Odense, Denmark (a secondary and tertiary referral allergy unit) and Viborg County Hospital, Viborg, Denmark (a secondary referral allergy unit) from September 2017 to December 2021 were consecutively included in the study. The children either presented with a case history of a likely clinical allergic reaction to ingestion of hen's egg or presented with moderate-to-severe atopic eczema and were sensitized to egg white. A pediatric allergist took a thorough case history, and specific IgE to hen's egg white and ovomucoid (Gal d 1) were measured by ImmunoCAP® (Thermo Fisher, Uppsala, Sweden). An open titrated OFC with raw pasteurized hen's egg was performed in all children to confirm or reject the

clinical suspicion of egg allergy. The raw egg was served with either sugar or fruit puree on the top. Pasteurization of egg has proven not to alter the allergenicity of fresh egg.(4) The children were not challenged with baked egg.

From September 2017 to February 2019, a 6-step protocol with 30-minutes dosing intervals was used and from February 2019 to December 2021 it was changed to a 4-step protocol with 60 minutes intervals.

The 6 step protocol was: Time 0: 0.05g, Time 30min: 0.25g, Time 60min: 1g, Time 90min: 5g, Time 120min: 20g, Time 150min: 25g. The 4-step protocol was: Time 0: 0.05g, Time 60min: 0.25g, Time 120min: 6g, Time 180min: 45g.

Hence, the first two doses were identical and the cumulative dose was equal, 51.30 g egg corresponding to approximately one hen's egg. The OFC was considered positive only in case of objective clinical reactions within two hours after the last administered dose. Skilled allergy nurses and an experienced pediatric allergist performed all provocations.

Study data were prospectively collected and managed using REDCap electronic data capture tools hosted at Odense University Hospital. The database was approved by The Danish Data Protection Agency and registered in ClinicalTrials.gov (NCT04331522). Written consent to include data in the database for subsequent publication was obtained from all subjects or their parents in case of age < 15 years.

During the study period, 288 OFCs with egg were performed. In case children had more than one OFC during the study period only data from the first OFC were included. Out of 91 OFCs using the 30-minutes protocol, 52 (57%) were positive and out of 197 OFCs using the 60-minutes protocol, 94 (48%) were positive. Consequently, 146 children aged 6 months to 15 years with a positive OFC with egg were included in the study.

There were no significant differences between baseline characteristics of the children in the 30-minutes and the 60-minutes protocol group (Table 1).

One child (2%) in the 30-minutes group and two children (2%) in the 60-minutes group were treated with intramuscular adrenaline due to anaphylaxis defined as severe respiratory or cardiovascular symptoms. (5) No subjects developed hypotension.

Table 2 shows the outcomes of the OFC's. Significantly more subjects in the 30-minutes group compared with the 60-minutes group had symptoms from more than one organ system: 46% (95% CI: 32%; 61%) versus 30% (95% CI: 21%; 40%),  $p=0.048$ , risk difference: 16% (95%CI: 0.4%; 33%).

In the 60-minutes group, significantly more subjects reacted to the first dose compared with the 30-minutes group: 26% (95% CI: 17%; 36%) versus 6% (95% CI: 1%; 16%),  $p=0.003$ , risk difference: 20% (95% CI: 9%; 31%). In the 60-minutes protocol group the allergic reaction occurred more than 30 minutes after the last administered dose in 29 (31%) of the children: eight children (9%) after 31-45 minutes and 21 children after more than 45 minutes.

The number of children that reacted to one of the first two doses was 12 (26%) in the 30-minutes group and 37 (39%) in the 60-minutes group. Of these 49 children, 40 (82%) only had symptoms from a single organ system compared with 54 (56%) of the 97 children reacting to a cumulative dose of 1.3g or more ( $p=0.004$ ).

The results suggest that in case of raw egg, a 60-minutes observation period before administering the next dose allows significantly more subjects to react to the first provided doses. Our data shows that 6% versus 26% of egg allergic children elicit objective allergic symptoms after ingesting 0.05g raw egg if you wait 30 versus 60 minutes, respectively, before administering the second dose, corresponding to a risk ratio of 4.4. Similarly, a retrospective study comparing 30-, 40- and

60-minutes interval for OFC with low-dose boiled egg white found that a 60-minutes interval resulted in significantly lower symptom scores and in addition, a lower total dose.(3)

Another recent study also indicated that the time from ingestion to the allergen elicits an allergic reaction is longer for egg than milk with a median time to onset of symptoms of 75 minutes for OFC with heated hen's egg powder(2) and 50 minutes for scrambled egg.(1)

Several studies imply a more important role of ovomucoid compared with other allergenic proteins in egg and the presence of ovomucoid-specific IgE appears to be a good predictor of clinical allergy to egg.(6) Ovomucoid is a potent trypsin inhibitor and has a structural stability that makes the molecule maintain epitopes during the passage through the gastrointestinal tract.(7) Ovomucoid fragments still have IgE-binding activity after pepsin degradation and the pepsin degradation products retain trypsin inhibitor activity (8). These characteristics may imply that ovomucoid compared to other allergens can interact with the intestinal mucosa for a longer time, and hence may explain why time from ingestion to allergic reaction may be longer for egg than other allergens.(7)

The choice of dosing interval when performing OFCs is challenging. A too short interval increases the risk that the patients do not react to the last administered dose. In addition, too short intervals and too small increments in doses may induce a state of temporary desensitization.(9) Increasing the intervals has the disadvantage of a longer OFC time. We tried to overcome this burden by reducing the number of doses. Consequently, more children ingested the maximal dose of 51.3g egg, but this was overall not associated with more severe reactions compared with the 30-minutes protocol.

The study has the strength of including children from both a regional pediatric hospital and a university hospital. We acknowledge several limitations in this study. This was not a randomized

double-blinded and placebo-controlled study. However, the baseline characteristics were very similar in the two groups and as only objective immediate reactions were considered positive, assessment bias is limited. Young children with eczema (82%) dominated the study population.

Young children may have reduced ability to digest the proteins in egg white and findings may be different in older children.(7)

In conclusion, the present study suggests that increasing the dosing interval from 30 to 60 minutes when performing OFCs with raw pasteurized egg may result in more children reacting to a lower dose.

#### **Figure legends**

Table 1

Demographics and clinical characteristics of the children in the 30-minutes- and the 60-minutes-interval group. Data are expressed as n(%) or medians [interquartile range].

Table 2

The symptoms and the eliciting doses for the OFC's with the 30-minutes interval protocol and the 60-minutes interval protocol, respectively. Data are expressed as n (%). p-values are calculated using Chi-squared-test or Fisher's exact test

## References

1. Yanagida N, Minoura T, Kitaoka S. Allergic reactions to milk appear sooner than reactions to hen's eggs: a retrospective study. *World Allergy Organ J.* 2016;9:12.
2. Yanagida N, Sato S, Takahashi K, Ohtani K, Emura S, Shibukawa Y, et al. Timing of onset of allergic symptoms following low-dose milk and egg challenges. *Pediatr Allergy Immunol.* 2021;32(3):612-5.
3. Kitamura K, Makino A, Matsui T, Takasato Y, Sugiura S, Ito K. A 60-minute dosing interval is safer than a 30- or 40-minute interval in oral food challenge. *Allergol Int.* 2021.
4. Netting M, Donato A, Makrides M, Gold M, Quinn P, Penttila I. Allergenicity of pasteurized whole raw Hen's egg compared with fresh whole raw Hen's egg. *Pediatr Allergy Immunol.* 2015;26(3):234-8.

5. Cox LS, Sanchez-Borges M, Lockey RF. World Allergy Organization Systemic Allergic Reaction Grading System: Is a Modification Needed? *J Allergy Clin Immunol Pract.* 2017;5(1):58-62.e5.
6. Ando H, Movérare R, Kondo Y, Tsuge I, Tanaka A, Borres MP, et al. Utility of ovomucoid-specific IgE concentrations in predicting symptomatic egg allergy. *J Allergy Clin Immunol.* 2008;122(3):583-8.
7. Benedé S, López-Expósito I, Molina E, López-Fandiño R. Egg proteins as allergens and the effects of the food matrix and processing. *Food Funct.* 2015;6(3):694-713.
8. Jiménez-Saiz R, Belloque J, Molina E, López-Fandiño R. Human immunoglobulin E (IgE) binding to heated and glycated ovalbumin and ovomucoid before and after in vitro digestion. *J Agric Food Chem.* 2011;59(18):10044-51.
9. Niggemann B, Lange L, Finger A, Ziegert M, Müller V, Beyer K. Accurate oral food challenge requires a cumulative dose on a subsequent day. *J Allergy Clin Immunol.* 2012;130(1):261-3.

**Table 1. Patient characteristics**

|                               | 30-min-protocol   | 60-min-protocol   | p-value |
|-------------------------------|-------------------|-------------------|---------|
| N                             | 52                | 94                |         |
| Site                          |                   |                   | 0.799   |
| University Hospital           | 31 (60%)          | 54 (57%)          |         |
| Regional Pediatric Department | 21 (40%)          | 40 (43%)          |         |
| Age (mths)                    | 22 [13;33]        | 17 [12;28]        | 0.112   |
| Gender, male                  | 29 (56%)          | 66 (70%)          | 0.080   |
| Spec IgE eggwhite (kU/L)      | 2.70 [0.89; 5.77] | 3.09 [1.20; 7.30] | 0.759   |
| Spec IgE ovomucoid (kU/L)     | 0.96 [0.00; 3.94] | 1.47 [0.00; 6.13] | 0.799   |
| Reason for provocation        |                   |                   | >0.9    |
| Immediate reaction            | 35 (67%)          | 64 (68%)          |         |
| Eczema and sensitization      | 17 (33%)          | 30 (32%)          |         |
| Comorbidities                 |                   |                   |         |
| Asthma/recurrent wheeze       | 14 (27%)          | 20 (22%)          | 0.460   |
| Rhinoconjunctivitis           | 10 (19%)          | 9 (10%)           | 0.108   |
| Eczema                        | 42 (81%)          | 78 (84%)          | 0.635   |

Table 2. Results

|                                                                                        | 30-min-protocol<br>n=52 |              | 60-min-protocol<br>n=94 |              | p-value |
|----------------------------------------------------------------------------------------|-------------------------|--------------|-------------------------|--------------|---------|
| <b>Skin symptoms</b>                                                                   | <b>47</b>               | <b>(90%)</b> | <b>79</b>               | <b>(84%)</b> | 0.286   |
| Urticaria                                                                              | 39                      | (75%)        | 73                      | (78%)        | 0.829   |
| localized urticaria                                                                    | 33                      | (63%)        | 54                      | (57%)        | 0.478   |
| generalized urticaria                                                                  | 6                       | (12%)        | 19                      | (20%)        | 0.183   |
| Angioedema                                                                             | 7                       | (13%)        | 7                       | (7%)         | 0.237   |
| Flushing                                                                               | 11                      | (21%)        | 9                       | (10%)        | 0.051   |
| Acute flare of eczema                                                                  | 5                       | (10%)        | 11                      | (12%)        | 0.699   |
| <b>Gastrointestinal symptoms</b>                                                       | <b>15</b>               | <b>(29%)</b> | <b>25</b>               | <b>(27%)</b> | 0.770   |
| Vomiting                                                                               | 15                      | (29%)        | 23                      | (24%)        | 0.564   |
| Diarrhea                                                                               | 2                       | (4%)         | 3                       | (3%)         | >0.9    |
| <b>Respiratory symptoms</b>                                                            | <b>19</b>               | <b>(37%)</b> | <b>22</b>               | <b>(23%)</b> | 0.091   |
| Rhinoconjunctivitis                                                                    | 18                      | (35%)        | 17                      | (18%)        | 0.025   |
| Asthma/Wheeze                                                                          | 2                       | (4%)         | 5                       | (5%)         | >0.9    |
| <b>Severity</b>                                                                        |                         |              |                         |              |         |
| Skin only                                                                              | 25                      | (48%)        | 55                      | (59%)        | 0.225   |
| Gastrointestinal only                                                                  | 2                       | (4%)         | 9                       | (10%)        | 0.178   |
| Respiratory only                                                                       | 1                       | (2%)         | 2                       | (2%)         | >0.9    |
| Hypotension                                                                            | 0                       | (0%)         | 0                       | (0%)         | >0.9    |
| >1 organ system                                                                        | 24                      | (46%)        | 28                      | (30%)        | 0.048   |
| 3 organ systems                                                                        | 5                       | (10%)        | 4                       | (4%)         | 0.281   |
| Adrenaline use                                                                         | 1                       | (2%)         | 2                       | (2%)         | >0.9    |
| <b>Cumulative dose</b> (median, IQR)                                                   | 6.3g                    | [1.3;26.3]   | 6.3g                    | [0.05;26.3]  | >0.9    |
| <b>Number of children reacting to each of the cumulative doses</b>                     | 0.05g:                  | 3 (6%)       | 24                      | (26%)        |         |
|                                                                                        | 0.30g:                  | 9 (17%)      | 13                      | (14%)        |         |
|                                                                                        | 1.30g:                  | 13 (25%)     |                         |              |         |
|                                                                                        | 6.30g:                  | 12 (23%)     | 33                      | (35%)        |         |
|                                                                                        | 26.30g:                 | 12 (23%)     |                         |              |         |
|                                                                                        | 51.30g:                 | 3 (6%)       | 24                      | (26%)        |         |
| <b>Proportion of children having symptoms from only one organ system for each dose</b> | 0.05g:                  | 3/3 (100%)   | 21/24                   | (88%)        |         |
|                                                                                        | 0.30g:                  | 6/9 (67%)    | 10/13                   | (77%)        |         |
|                                                                                        | 1.30g:                  | 6/13 (46%)   |                         |              |         |
|                                                                                        | 6.30g:                  | 8/12 (67%)   | 17/33                   | (52%)        |         |
|                                                                                        | 26.30g:                 | 4/12 (33%)   |                         |              |         |
|                                                                                        | 51.30g:                 | 1/3 (33%)    | 18/24                   | (75%)        |         |

|  |  |
|--|--|
|  |  |
|--|--|